Senores Pharma reported a strong set of financial numbers for the third quarter, delivering sharp year-on-year growth across profitability and revenue metrics.
The company’s net profit nearly doubled during the quarter, rising 88% to ₹32 crore compared with ₹17 crore in the corresponding period last year. The improvement in earnings reflects better operating leverage and a higher scale of business execution during the quarter.
Revenue for Q3 increased significantly by 69.4% year-on-year to ₹174.5 crore, up from ₹103 crore in the same quarter of the previous financial year. The strong top-line growth indicates robust performance across key business segments during the period under review.
Operating performance also strengthened notably, with EBITDA rising to ₹54 crore compared with ₹25.4 crore a year ago. EBITDA margins expanded to 31% from 25% on a year-on-year basis, highlighting improved operational efficiency and cost management.
